Zacks: Analysts Expect Denali Therapeutics Inc. (NASDAQ:DNLI) to Announce -$0.67 EPS

Wall Street analysts expect that Denali Therapeutics Inc. (NASDAQ:DNLIGet Rating) will report earnings of ($0.67) per share for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have made estimates for Denali Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.54) and the lowest estimate coming in at ($0.87). Denali Therapeutics reported earnings of ($0.50) per share in the same quarter last year, which suggests a negative year over year growth rate of 34%. The company is expected to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Denali Therapeutics will report full year earnings of ($2.60) per share for the current year, with EPS estimates ranging from ($2.84) to ($2.15). For the next fiscal year, analysts expect that the business will report earnings of ($2.46) per share, with EPS estimates ranging from ($3.07) to ($1.03). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Denali Therapeutics.

Denali Therapeutics (NASDAQ:DNLIGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). Denali Therapeutics had a negative net margin of 597.15% and a negative return on equity of 27.99%. The firm had revenue of $42.10 million for the quarter, compared to the consensus estimate of $33.32 million. During the same quarter last year, the firm earned ($0.58) EPS. The company’s revenue was up 432.9% on a year-over-year basis.

A number of research analysts have recently commented on DNLI shares. Wedbush cut their price target on shares of Denali Therapeutics from $62.00 to $48.00 in a report on Friday. TheStreet cut shares of Denali Therapeutics from a “c-” rating to a “d” rating in a report on Wednesday, March 2nd. Finally, The Goldman Sachs Group cut their price target on shares of Denali Therapeutics from $114.00 to $98.00 and set a “buy” rating on the stock in a report on Monday, March 7th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Denali Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $81.67.

DNLI stock opened at $23.05 on Friday. The firm’s fifty day simple moving average is $30.28 and its two-hundred day simple moving average is $38.06. The stock has a market capitalization of $2.83 billion, a price-to-earnings ratio of -9.64 and a beta of 1.90. Denali Therapeutics has a twelve month low of $22.52 and a twelve month high of $79.70.

In related news, Director Marc Tessier-Lavigne sold 20,000 shares of the company’s stock in a transaction dated Wednesday, March 23rd. The shares were sold at an average price of $33.83, for a total value of $676,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Carole Ho sold 2,918 shares of the stock in a transaction dated Friday, February 11th. The shares were sold at an average price of $34.71, for a total transaction of $101,283.78. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 43,210 shares of company stock valued at $1,496,386. 17.00% of the stock is owned by insiders.

Hedge funds have recently added to or reduced their stakes in the business. HM Payson & Co. purchased a new stake in shares of Denali Therapeutics during the fourth quarter valued at about $26,000. Lindbrook Capital LLC purchased a new stake in shares of Denali Therapeutics during the fourth quarter valued at about $27,000. Dark Forest Capital Management LP lifted its position in shares of Denali Therapeutics by 19,733.3% during the third quarter. Dark Forest Capital Management LP now owns 595 shares of the company’s stock valued at $30,000 after buying an additional 592 shares during the last quarter. Patriot Financial Group Insurance Agency LLC lifted its position in shares of Denali Therapeutics by 125.3% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 811 shares of the company’s stock valued at $36,000 after buying an additional 451 shares during the last quarter. Finally, Point72 Hong Kong Ltd purchased a new stake in shares of Denali Therapeutics during the third quarter valued at about $45,000. 72.32% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile (Get Rating)

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.

Read More

Get a free copy of the Zacks research report on Denali Therapeutics (DNLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.